Sign Up
OverviewAPI
Despite layoffs and declining stock values, the biotech sector is showing signs of improvement. Falling borrowing costs and increased pharma deal activity indicate a potential recovery. Investors are advised to consider long-term strategies in this turbulent period.

Ask a question